膀胱癌现有全身用药及新兴疗法的新型给药机制
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.
作者信息
Zhang Jj H, Starr Savannah L, Chamie Karim
机构信息
Department of Urology, UCLA Medical Center, Los Angeles, CA, USA.
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
出版信息
Bladder Cancer. 2023 Jun 27;9(2):109-123. doi: 10.3233/BLC-220114. eCollection 2023.
Abstract
Systemic agents including immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies play a critical role in the management of bladder cancer. Novel localized delivery mechanisms for existing systemic agents explore solutions to improve treatment response without compromising safety. Herein, we review the contemporary innovations in modern intravesical agents, hyperthermic drug delivery, reverse-thermal gels, nanocarriers, gene therapy, and subcutaneous therapies.
摘要
包括免疫检查点抑制剂、抗体药物偶联物和靶向疗法在内的全身用药在膀胱癌治疗中发挥着关键作用。针对现有全身用药的新型局部给药机制探索了在不影响安全性的前提下改善治疗反应的解决方案。在此，我们综述了现代膀胱内用药、热疗药物递送、逆温凝胶、纳米载体、基因治疗和皮下治疗方面的当代创新成果。
相似文献
1
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.膀胱癌现有全身用药及新兴疗法的新型给药机制
Bladder Cancer. 2023 Jun 27;9(2):109-123. doi: 10.3233/BLC-220114. eCollection 2023.
2
Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.非肌层浸润性膀胱癌的药物治疗：现状与未来治疗方法
Arch Pharmacol Ther. 2022;4(1):13-22.
3
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.抗腺病毒抗体预测 Nadofaragene Firadenovec 治疗卡介苗无应答性非肌肉浸润性膀胱癌的反应持久性：III 期临床试验的二次分析。
Eur Urol. 2022 Mar;81(3):223-228. doi: 10.1016/j.eururo.2021.12.009. Epub 2021 Dec 18.
4
Mechanism of action of nadofaragene firadenovec-vncg.纳多法基因菲拉地诺韦克 - vncg的作用机制。
Front Oncol. 2024 Mar 15;14:1359725. doi: 10.3389/fonc.2024.1359725. eCollection 2024.
5
Nadofaragene Firadenovec: First Approval.那度鲁胺：首次批准
Drugs. 2023 Mar;83(4):353-357. doi: 10.1007/s40265-023-01846-z.
6
The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.目前针对卡介苗无反应性非肌肉浸润性膀胱癌患者的挽救治疗现状。
Curr Opin Urol. 2021 May 1;31(3):178-187. doi: 10.1097/MOU.0000000000000863.
7
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.用 nadofaragene firadenovec 进行干扰素基因治疗膀胱癌：从实验室到批准。
Front Immunol. 2023 Aug 29;14:1260498. doi: 10.3389/fimmu.2023.1260498. eCollection 2023.
8
Emerging role of checkpoint inhibition in localized bladder cancer.检查点抑制在局限性膀胱癌中的新作用。
Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21.
9
Contemporary Systemic Therapies in Urothelial Carcinoma. Contemporary 系统疗法在尿路上皮癌中的应用。
Urology. 2023 Apr;174:150-158. doi: 10.1016/j.urology.2023.01.007. Epub 2023 Jan 20.
10
Bladder cancer: shedding light on the most promising investigational drugs in clinical trials.膀胱癌：探索临床试验中最有前途的研究药物。
Expert Opin Investig Drugs. 2021 Aug;30(8):837-855. doi: 10.1080/13543784.2021.1948999. Epub 2021 Jul 14.
本文引用的文献
1
IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.白细胞介素-15 超级激动剂 NAI 在卡介苗无应答性非肌肉浸润性膀胱癌中的作用。
NEJM Evid. 2023 Jan;2(1):EVIDoa2200167. doi: 10.1056/EVIDoa2200167. Epub 2022 Nov 10.
2
The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non-muscle-invasive Bladder Cancer.局部递送的检查点抑制剂在非肌层浸润性膀胱癌中不断演变的作用
Eur Urol. 2022 Dec;82(6):611-612. doi: 10.1016/j.eururo.2022.08.032. Epub 2022 Sep 22.
3
Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors.恩沃利单抗——首款用于微卫星高度不稳定或错配修复缺陷的晚期实体瘤的皮下注射用PD-1/PD-L1抗体。
Expert Opin Biol Ther. 2022 Oct;22(10):1227-1232. doi: 10.1080/14712598.2022.2125799. Epub 2022 Sep 20.
4
First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.首次人体膀胱内注射派姆单抗可识别卡介苗治疗无应答的膀胱癌中的免疫激活。
Eur Urol. 2022 Dec;82(6):602-610. doi: 10.1016/j.eururo.2022.08.004. Epub 2022 Aug 23.
5
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.辅助性膀胱内化疗热疗与中危非肌肉浸润性膀胱癌患者的被动化疗（HIVEC-II）：一项 2 期、开放标签、随机对照试验。
Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20.
6
Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning.新型膀胱内治疗药物在非肌层浸润性膀胱癌治疗中的应用：前沿扫描
Front Surg. 2022 Jul 26;9:912438. doi: 10.3389/fsurg.2022.912438. eCollection 2022.
7
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.NCCN 指南®洞察：膀胱癌，第 2.2022 版。
J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041.
8
A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.卡介苗无反应性非肌层浸润性膀胱癌患者膀胱内光动力疗法的1b期临床研究
Eur Urol Open Sci. 2022 Jun 1;41:105-111. doi: 10.1016/j.euros.2022.04.015. eCollection 2022 Jul.
9
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.一项新辅助 Sasanlimab 和立体定向体部放疗作为顺铂禁忌型 MIBC 疫苗的 II 期临床试验：RAD VACCINE MIBC 试验。
Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15.
10
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.在非肌肉浸润性膀胱癌成人患者的一线治疗中使用化疗消融凝胶（UGN-102）的最小患者报告副作用。
J Urol. 2022 Sep;208(3):580-588. doi: 10.1097/JU.0000000000002747. Epub 2022 May 31.
Zotero 插件